SLAMF7 and non-Hodgkin lymphoma: Gamida Cell has entered the clinical stage with a Phase I trial with their first PB-NK-derived product GDA-201, administered in combination with Elotuzumab (anti-SLAMF7 mAb) in MM patients or with Rituximab (anti-CD20 mAb) in NHL patients, to facilitate tumor targeting and ADCC (NCT03019666, Additional file 1: Table S1, row 12 and Additional file 3: Table S3, row 30).